계명대학교 의학도서관 Repository

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma

Metadata Downloads
Author(s)
Keon Woo ParkHo Sup LeeWon-Sik LeeSang Min LeeJeong-Ok LeeMin Kyoung KimKihyun KimChang-Ki MinJae-Yong KwakSang-Byung BaeSung-Soo YoonJe-Jung LeeKi Hwan KimSeung-Hyun NamYeung-Chul MunHyo Jung KimSung Hwa BaeHo-Jin ShinJung-Hee LeeJoon Seong ParkSeong Hyun JeongMark Hong LeeYang-Soo KimSung-Nam LimJae Hoon LeeDo-Yeun ChoYoung Rok DoJeong-A KimSeong Kyu ParkJin Seok KimSoo-Jeong KimHawk KimHyeon Gyu YiJoon Ho MoonChul Won ChoiSung-Hyun KimYoung-Don JooHoon-Gu KimByung Soo KimMoo-Rim ParkMoo-Kon SongSu-Youn KimMyung Soo HyunDeog Yeon Jo
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
Oncotarget
Issued Date
2017
Volume
8
Issue
23
Keyword
multiple myelomaagedbortezomibdrug therapycombination
Abstract
Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM.

Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS).

Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. ≥ 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. ≥ 35.1 mg/m2; p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP.

In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients.
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine
Citation
Keon Woo Park et al. (2017). A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget, 8(23), 37605–37618. doi: 10.18632/oncotarget.16790
Type
Article
ISSN
1949-2553
DOI
10.18632/oncotarget.16790
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32541
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Authorize & License
  • Authorize공개
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.